Vol 81, Supp. I (2023): Zeszyty Edukacyjne 1/2023
Artykuł poglądowy
Published online: 2023-09-27
Peryndopryl — formuła XXI wieku. A never ending story
DOI: 10.33963/v.kp.96130
Abstract
Peryndopryl jest lekiem z grupy inhibitorów enzymu konwertującego angiotensynę I do angiotensyny II. W pracy omówiono różnorakie mechanizmy działania leku, efektem których jest działanie hipotensyjne, naczynioprotekcyjne, kardioprotekcyjne, przeciwzapalne. Mechanizmy te przekładają się na działanie antymiażdżycowe, wykorzystywane w leczeniu nadciśnienia tętniczego, jak i choroby niedokrwiennej serca. W tej ostatniej, pomimo agresywnego leczenia farmakologicznego i interwencyjnego lek nadal wnosi „wartość dodaną” do złożonego leczenia, redukując ryzyko śmiertelności sercowo-naczyniowej oraz kolejnych zawałów serca. W redukcji ryzyka powikłań miażdżycowych jest skuteczniejszy od sartanów, równie skuteczny jak ramipryl, szczególnie u chorych w wieku podeszłym. Wyjątkowe korzyści odnoszą chorzy z nadciśnieniem tętniczym i powikłaniami miażdżycowymi oraz chorzy z przewlekłym zespołem wieńcowym po przebytym zawale serca.
Keywords: ACEinadciśnienie tętniczeperyndoprylprzewlekły zespół wieńcowy
References
- Lon EM, Bosch J, Flather M, Yusuf S. Vascular and anti-ischaemic effects of ACE Inhibitors: Current Evidence and ongoing clinical trials. In: Yusuf S, Wilhelmsen L. ed. Advanced Issues in Prevention and Treatment of Atherosclerosis. Proceedings of the Symposium held at Amsterdam on Wednesday, August 23, 1995. Copyright Hochest Aktiengessellshaft IBBN .
- Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016; 16(5): 309–321.
- Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007; 577(1–3): 1–6.
- Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003; 41(6): 1281–1286.
- Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation. 1996; 94(12): 3115–3122.
- Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007; 73(1): 237–246.
- Ceconi C, Francolini G, Bastianon D, et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther. 2007; 21(6): 423–429.
- Cangiano E, Marchesini J, Campo G, et al. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs. 2011; 11(3): 189–198.
- Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996; 94(11): 2756–2767.
- Zhuo JL, Mendelsohn FAO, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002; 39(2 Pt 2): 634–638.
- Lévy BI. Can angiotensin II type 2 receptors have deleteorious effects in cardiovascular disease? Implication for therapeutic blockade of the renin-angiotensin system. Circulation. 2004; 109(1): 8–13.
- Campbell JH, Fennessy P, Campbell GR, et al. Effect of perindopril on the development of atherosclerosis in the cholesterol-fed rabbit. Clin Exp Pharmacol Physiol Suppl. 1992; 19(1): 13–17.
- Okrucká A, Pechán J, Kratochvílová H. Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. Platelets. 1998; 9(1): 63–67.
- Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation. 2002; 105(16): 2000–2004.
- Timmis AD. Plaque stabilisation in acute coronary syndromes: clinical considerations. Heart. 2003; 89(10): 1268–1272.
- Bruining N, de Winter S, Roelandt JR, et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis. 2009; 20(6): 409–414.
- Turnbull F, Neal B, Pfeffer M, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007; 25(5): 951–958.
- Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006; 114(8): 838–854.
- Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005; 46(2): 386–392.
- Awad K, Zaki MM, Mohammed M, et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2022; 97(10): 1808–1823.
- Wang XM, Li Y, Li HF, et al. Effects of perindopril on soluble intercellular adhesion molecule-1 in patients with congestive heart failure. Heart. 2002; 88(4): 417.
- Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002; 15(4 Pt 1): 316–320.
- Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol. 1998; 32(4): 616–620.
- Matsumoto T, Minai K, Horie H, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol. 2003; 41(8): 1373–1379.
- Schwartzkopff B, Brehm M, Mundhenke M, et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000; 36(2): 220–225.
- Mizuno Y, Yasue H, Yoshimura M, et al. Effects of perindopril on aldosterone production in the failing human heart. Am J Cardiol. 2002; 89(10): 1197–1200.
- Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol. 2002; 88(1): 100–107.
- Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006; 166(6): 659–666.
- Morgan TO, Anderson A. Different drug classes have variable effects on blood pressure depending on the time of day. Am J Hypertens. 2003; 16(1): 46–50.
- Symonides B, Gaciong Z. Znaczenie leków w formie o powolnym uwalnianiu w terapii nadciśnienia tętniczego i jego powikłań. Arterial Hypertension. 2002; 6(2): 107–112.
- PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient. Lancet. 2001; 358: 1033–1041.
- Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782–788.
- Dahlöf B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
- Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829–840.
- Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887–1898.
- Beckett N, Peters R, Tuomilehto J, et al. HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ. 2011; 344: d7541.
- Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364): 1149–1158.
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957–967.
- Grajek S. Kompleksowe leczenie chorych z nadciśnieniem tętniczym — nie tylko redukcja ciśnienia tętniczego. Choroby Serca i Naczyń. 2017; 14(6): 1–16.
- Williams B, Lacy PS, Thom SM, et al. CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113(9): 1213–1225.
- Grajek S. Inhibitory enzymu konwertazy angiotensyny u pacjentów z zawałem serca — zmiana paradygmatu. Kardiol Pol. 2016; 74(Suppl II): 13–18.
- Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006; 27(24): 2982–2988.
- Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000; 102(13): 1503–1510.
- Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292(18): 2217–2225.
- Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010; 159(5): 795–802.
- Bertrand ME, Vlachopoulos C, Mourad JJ. Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. Am J Cardiovasc Drugs. 2016; 16(4): 241–253.
- van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16): 2088–2097.
- Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009; 30(11): 1385–1394.
- Yusuf S, Pitt B, Davis CE, et al. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325(5): 293–302.
- Yusuf S, Pitt B, Davis CE, et al. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327(10): 685–691.
- Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992; 340(8829): 1173–1178.
- Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10): 669–677.
- Rutherford JD, Pfeffer MA, Moyé LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation. 1994; 90(4): 1731–1738.
- Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145–153.
- Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386): 782–788.
- Grajek S. Krajobraz po PEACE. Czy wszystkie inhibitory ACE działają jednakowo? Folia Cardiol. 2005; 12: 145–152.
- Grajek S. EUROPA i inne badania — znaczenie peryndoprilu w leczeniu choroby niedokrwiennej serca. Folia Cardiol. 2004; 11: 75–78.
- Grajek S. The landscape after PEACE: do all ACE inhibitors act in an identical way? Curr Med Res Opin. 2006; 22(2): 265–274.
- Grajek S. Nowoczesna protekcja w nadciśnieniu tętniczym i przewlekłym zespole wieńcowym. Choroby Serca i Naczyń. 2020; 17(2): 84–95.
- Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995; 332(2): 80–85.
- Borghi C, Bacchelli S, Esposti DD, et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens. 1999; 12(7): 665–672.
- Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med. 2006; 166(7): 787–796.
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1–86.
- Fox KM, Bertrand ME, Remme WJ, et al. EUROPA Investigators. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J. 2007; 153(4): 629–635.
- Pitt B, O'Neill B, Feldman R, et al. QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001; 87(9): 1058–1063.
- Rouleau JL, Warnica WJ, Baillot R, et al. IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008; 117(1): 24–31.
- Braunwald E, Domanski M, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351(20): 2058–2068.
- Dagenais GR, Yusuf S, Bourassa MG, et al. HOPE Investigators. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001; 104(5): 522–526.
- Hoang V, Alam M, Addison D, et al. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern statin era: a meta-analysis of randomized-controlled trials. Cardiovasc Drugs Ther. 2016; 30(2): 189–198.
- Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004; 18(11): 781–788.
- Radhoe SP, Boersma E, Bertrand M, et al. The effects of a perindopril-based regimen in relation to statin use on the outcomes of patients with vascular disease: a combined analysis of the ADVANCE, EUROPA, and PROGRESS trials. Cardiovasc Drugs Ther. 2022 [Epub ahead of print].
- Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomized controlled trial. Lancet. 2018; 391(10115): 31–40.
- Bangalore S, Fakheri R, Toklu B, et al. Angiotensin-Converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016; 91(1): 51–60.
- Messerli FH, Bangalore S. Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation. 2017; 135(22): 2085–2087.
- Strauss MH, Hall AS. Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality. Further evidence for the ARB-MI Paradox. Circulation. 2017; 135(22): 2088–2090.
- Messerli FH, Bangalore S, Bavish C, et al. Angiotensin-converting enzyme inhibitors in hypertension. To use or not to use? J Am Coll Cardiol. 2018; 71(13): 1474–1482.
- Messerli FH, Bavishi C, Bangalore S. Why are we still prescribing angiotensin-converting enzyme inhibitors? Circulation. 2022; 145(6): 413–415.
- Grajek S, Marcinkowska J. TRANSCEND i inne badania. Głos w debacie o ryzyku zawału serca u chorych leczonych inhibitorami enzymu konwertującego lub inhibitorami receptora angiotensyny. Nadciśnienie Tętnicze. 2009; 13(1): 1–11.
- Yusuf S, Teo KK, Pogue J, et al. The ONTARGET Investigators. Telmisartan, ramipril, or both in pptients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547–1559.
- Hara M, Sakata Y, Nakatani D, et al. OACIS Investigators. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Am J Cardiol. 2014; 114(1): 1–8.
- Choi InS, Park IeB, Lee K, et al. Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) investigators. Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge. J Cardiovasc Pharmacol Ther. 2018 [Epub ahead of print]: 1074248418795897.
- Kim YH, Her AY, Jeong MHo, et al. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents. Atherosclerosis. 2019; 289: 109–117.
- Lee JG, Joo SJ, Kim SY, et al. Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. PLoS One. 2023; 18(3): e0281460.
- MacMahon S, Chalmers J. Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. Eur Heart J. 2003; 24(5): 391–393.
- Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med. 2004; 141(2): 102–112.
- Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998; 97(22): 2202–2212.
- Myocardial infarction redefined — a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000; 21(18): 1502–1513.
- Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003; 24(1): 28–66.
- Van de Werf F, Bax J, Betriu A. Management of acute myocardial infarctionin patients presenting with persistent ST-segment elevation The Task Force on the management of ST-segment elevation acutemyocardial infarction of the European Society of Cardiology. Eur Heart J. 2008; 29(23): 2909–2945.
- Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137.
- Ahn W, Rha SW, Choi B, et al. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥ 65) patients with acute myocardial infarction without hypertension. Heart and Vessels. 2023; 38(7): 898–908.
- Bangalore S, Kumar S, Messerli F. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the physicians' desk reference. Am J Med. 2010; 123(11): 1016–1030.
- Brugts JJ, Arima H, Remme W, et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Int J Cardiol. 2014; 176(3): 718–723.
- Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021; 398(10306): 1133–1146.
- Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021; 397(10279): 1085–1094.
- Grajek S. Komentarz do artykułu” Mortality in STEMI patients without standard modifiable risk factors”. Choroby Serca i Naczyń. 2021; 18(2): 66–59.
- Kong G, Chin YH, Chong B, et al. Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients. Int J Cardiol. 2023; 371: 432–440.
